Preclinical Hematology R&D Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

In Vitro Hematology Modeling Services

Inquiry

At Ace Therapeutics, we provide comprehensive in vitro hematology modeling services to support preclinical research in blood-related disorders. Our service platforms integrate biologically relevant systems that simulate human hematopoiesis and disease pathophysiology, enabling accurate evaluation of drug efficacy, safety, and mechanism of action.

Service Overview

Our in vitro hematology services are structured to address key stages of drug evaluation, from early screening to mechanistic validation. We employ next-generation 3D culture technologies, iPSC-derived disease models, and primary human hematopoietic cells to deliver physiologically meaningful data that can inform lead candidate selection and optimization.

3D Human Hematopoietic Microenvironments

We utilize 3D biomimetic systems that more closely resemble the bone marrow niche compared to traditional 2D models. These systems are ideal for studying cell-cell interactions, tissue architecture, and microenvironmental influences on drug response.

Feature	Description
Tissue-specific extracellular matrices	Collagen scaffolds and synthetic hydrogels mimic stromal architecture
Dynamic gradients	Oxygen, nutrient, and cytokine gradients replicate marrow physiology
Multi-lineage co-culture	Includes stromal cells, endothelial cells, and CD34+ hematopoietic stem/progenitor cells (HSPCs)
Drug testing contexts	Predictive modeling of efficacy, cytotoxicity, and niche-targeting therapeutics

We also support 3D assays for CAR-T cell evaluation and immune-oncology testing, offering insights into cell persistence, activation, and hematopoietic toxicity in a controlled, disease-relevant setting.

iPSC-Derived Hematology Disease Models

For genetically defined or rare hematologic disorders, our iPSC-based models offer scalable, customizable platforms:

Derivation from patient fibroblasts or peripheral blood cells
Genome editing (e.g., CRISPR/Cas9) to generate isogenic controls or correct mutations
Differentiation into erythroid, myeloid, and megakaryocytic lineages
High-throughput drug testing across personalized genetic backgrounds

Primary Human Hematopoietic Cell Assays

Our ex vivo systems based on primary CD34+ HSPCs support disease-relevant functional assessments:

Sample sources: Bone marrow, mobilized peripheral blood, and umbilical cord blood (fresh or cryopreserved)
Disease-specific HSPCs: Including samples from myelodysplastic syndromes (MDS), myelofibrosis, and aplastic anemia
Colony-Forming Unit (CFU) Assays: Measure progenitor cell proliferation and differentiation
Long-Term Culture-Initiating Cell (LTC-IC) Assays: Assess self-renewal and multilineage potential
Custom autologous co-culture systems: Model patient-specific microenvironments

Specialized Functional Bioassays

We offer a suite of targeted assays for evaluating hematologic and vascular processes:

Assay Type	Application
Erythropoiesis assays	Track red cell maturation from CD34+ progenitors
Platelet aggregation	Evaluate thrombopoietic activity and anti-platelet agents
Endothelial interaction models	Simulate blood-endothelium crosstalk under inflammatory or thrombogenic conditions
Hemoglobin polymerization tests	Assess candidate therapies for sickle cell disease and β-thalassemia

These platforms can be adapted to early-stage screening, lead compound profiling, or mechanistic validation studies.

Mechanistic and Multi-Omic Readouts

To deliver actionable, mechanistic data, we combine traditional functional assays with multi-layered molecular profiling:

Single-cell RNA sequencing (scRNA-seq): Dissect cell lineage and transcriptional responses
Live-cell imaging: Monitor proliferation, mitochondrial stress, and apoptosis in real time
Metabolic assays: Analyze shifts in glycolysis, oxidative phosphorylation, and energy stress
Multiplex cytokine analysis: Detect hematopoietic regulators such as SCF, TPO, G-CSF

Why Choose Ace Therapeutics

Human-relevant systems tailored to specific hematologic disease contexts
Integrated 3D culture, iPSC-derived, and primary cell platforms
Custom assay development and dedicated scientific collaboration
Multi-parametric readouts combining functional and molecular data
Flexible service models to support exploratory or targeted preclinical research

Ace Therapeutics delivers in vitro hematology modeling services designed to enhance translational research and preclinical drug development. Our scientific platforms are ideal for biotech and pharmaceutical teams advancing novel therapies for blood-related diseases. To explore collaboration opportunities or discuss project feasibility, please contact us through our website.

Frequently Asked Questions (FAQs)

What types of hematologic diseases can be modeled with your services?

We support modeling of a broad range of conditions including MDS, aplastic anemia, hemoglobinopathies, and aging-related clonal disorders using primary cells or iPSC-derived systems.

Can assays be customized to fit our specific research goals?

Absolutely. We offer modular assay platforms that can be tailored to your needs, whether it's adding a stromal component, modifying culture conditions, or integrating additional analytical endpoints.

How do you ensure the relevance of your models to human hematopoiesis?

We use physiologically informed systems, including 3D culture conditions, primary human cells, and patient-specific iPSC models, which more accurately mimic the in vivo bone marrow microenvironment.

What type of data output can we expect?

Clients typically receive quantitative outputs from colony assays, flow cytometry, and molecular profiling, along with visual documentation from imaging platforms. Data is compiled in customizable report formats suitable for internal or external review.